MCID: MNT002
MIFTS: 56

Mental Depression

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 12 29 15 70
Depressive Disorder 70
Depression 44

Classifications:



External Ids:

Disease Ontology 12 DOID:1596
MeSH 44 D003863
NCIt 50 C2982
SNOMED-CT 67 41006004
ICD10 32 F32.9
UMLS 70 C0011570 C0011581

Summaries for Mental Depression

MalaCards based summary : Mental Depression, also known as depressive disorder, is related to postpartum depression and major depressive disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is DCTN1 (Dynactin Subunit 1), and among its related pathways/superpathways are cAMP signaling pathway and Serotonergic synapse. The drugs Reboxetine and Oxcarbazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1998)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 33.1 SLC6A4 POMC OXT NR3C1 MAOA HTR1A
2 major depressive disorder 32.9 SLC6A4 POMC OXT NR3C1 MAOA IL6
3 bipolar disorder 32.8 SLC6A4 PRODH NR3C1 MAOA IL6 HTR2A
4 atypical depressive disorder 32.5 SLC6A4 SERPINA3 POMC NR3C1 MAOA IL6
5 traumatic brain injury 32.4 IL6 COMT BDNF
6 neurotic disorder 32.4 SLC6A4 POMC OXT MAOA IL6 HTR2A
7 eating disorder 32.3 SLC6A4 POMC HTR2A CRH COMT BDNF
8 anxiety 32.3 SLC6A4 PRODH POMC OXT NR3C1 MAOA
9 fibromyalgia 32.3 SLC6A4 POMC IL6 HTR2A CRH COMT
10 depression 32.2 SLC6A4 NR3C1 MAOA HTR2A HTR1A CRH
11 schizoaffective disorder 32.2 SLC6A4 PRODH HTR2A HTR1A COMT BDNF
12 mood disorder 32.2 SLC6A4 PRODH POMC NR3C1 MAOA IL6
13 alcohol use disorder 32.2 SLC6A4 PRODH HTR2A HTR1A H2AC18 CRH
14 sleep apnea 32.2 SLC6A4 IL6 HTR2A BDNF
15 dysthymic disorder 32.1 SLC6A4 PRODH POMC MAOA IL6 HTR2A
16 dementia, lewy body 32.1 SERPINA3 H2AC18 COMT BDNF
17 asperger syndrome 32.0 SLC6A4 OXT COMT BDNF
18 parkinson disease, late-onset 32.0 SLC6A4 SERPINA3 PRODH MAOA HTR2A HTR1A
19 cyclothymic disorder 32.0 SLC6A4 HTR2A COMT
20 gilles de la tourette syndrome 32.0 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
21 migraine with or without aura 1 32.0 SLC6A4 POMC OXT MAOA IL6 HTR2A
22 generalized anxiety disorder 32.0 SLC6A4 NR3C1 MAOA HTR2A HTR1A COMT
23 body dysmorphic disorder 32.0 SLC6A4 OXT MAOA HTR2A
24 schizotypal personality disorder 32.0 PRODH HTR2A COMT
25 bulimia nervosa 32.0 SLC6A4 OXT MAOA HTR2A COMT BDNF
26 restless legs syndrome 31.9 SLC6A4 POMC MAOA COMT
27 post-traumatic stress disorder 31.9 SLC6A4 POMC NR3C1 MAOA HTR2A FKBP5
28 conversion disorder 31.9 HTR2A CRH COMT BDNF
29 brain injury 31.9 IL6 COMT BDNF
30 borderline personality disorder 31.9 SLC6A4 NR3C1 MAOA HTR2A HTR1A FKBP5
31 tardive dyskinesia 31.8 HTR2A COMT
32 panic disorder 31.8 SLC6A4 POMC MAOA HTR2A HTR1A CRH
33 acth-secreting pituitary adenoma 31.8 POMC NR3C1 CRH
34 personality disorder 31.8 SLC6A4 NR3C1 MAOA HTR2A HTR1A FKBP5
35 obsessive-compulsive disorder 31.8 SLC6A4 POMC OXT MAOA IL6 HTR2A
36 alcohol dependence 31.8 SLC6A4 POMC MAOA HTR2A HTR1A CRH
37 melancholia 31.7 SLC6A4 POMC MAOA IL6 HTR2A HTR1A
38 schizophrenia 31.7 SLC6A4 SERPINA3 PRODH POMC OXT NR3C1
39 autism spectrum disorder 31.7 SLC6A4 PRODH POMC OXT NR3C1 MAOA
40 respiratory failure 31.7 SERPINA3 IL6 H2AC18 DCTN1
41 arteries, anomalies of 31.7 SERPINA3 MIRLET7D MIR144 IL6 H2AC18
42 alexithymia 31.6 SLC6A4 OXT IL6 HTR1A COMT
43 bipolar i disorder 31.6 SLC6A4 HTR2A HTR1A COMT BDNF
44 pulmonary disease, chronic obstructive 31.6 SLC6A4 SERPINA3 NR3C1 MIR144 IL6 H2AC18
45 conduct disorder 31.6 SLC6A4 POMC MAOA COMT
46 endogenous depression 31.5 SLC6A4 POMC OXT NR3C1 MAOA IL6
47 acute stress disorder 31.5 SLC6A4 SERPINA3 POMC OXT NR3C1 IL6
48 agoraphobia 31.5 SLC6A4 MAOA HTR2A HTR1A CRH COMT
49 substance abuse 31.5 SLC6A4 SERPINA3 PRODH POMC MAOA IL6
50 adjustment disorder 31.5 SLC6A4 POMC OXT HTR2A HTR1A CRH

Graphical network of the top 20 diseases related to Mental Depression:



Diseases related to Mental Depression

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:


dejection emotional; depressed reaction; depression aggravated; affective symptoms; behavioral symptoms; schizophrenic language; depressive symptoms; depressed - symptom

MGI Mouse Phenotypes related to Mental Depression:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 BDNF COMT CRH DCTN1 FKBP5 HTR1A
2 homeostasis/metabolism MP:0005376 10.03 BDNF COMT CRH DCTN1 DPP4 FKBP5
3 endocrine/exocrine gland MP:0005379 9.96 BDNF COMT CRH DPP4 HTR2A IL6
4 integument MP:0010771 9.61 BDNF CRH IL6 NR3C1 OXT POMC
5 nervous system MP:0003631 9.44 BDNF COMT CRH DCTN1 FKBP5 HTR1A

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 762)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
2
Oxcarbazepine Approved Phase 4 28721-07-5 34312
3
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
4
Methimazole Approved Phase 4 60-56-0 1349907
5
Eleuthero Approved, Experimental Phase 4
6
Lactulose Approved Phase 4 4618-18-2 11333
7
Copper Approved, Investigational Phase 4 7440-50-8 27099
8
Norethindrone Approved Phase 4 68-22-4 6230
9
Lithium carbonate Approved Phase 4 554-13-2
10
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 5324346 3404
11
Ethanol Approved Phase 4 64-17-5 702
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13
Ziprasidone Approved Phase 4 146939-27-7 60854
14
Haloperidol Approved Phase 4 52-86-8 3559
15
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
16
Desipramine Approved, Investigational Phase 4 50-47-5 2995
17
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
18
Memantine Approved, Investigational Phase 4 19982-08-2 4054
19
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
20
Methyltestosterone Approved Phase 4 58-18-4 6010
21
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
22
Testosterone enanthate Approved Phase 4 315-37-7 9416
23
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
24
Topiramate Approved Phase 4 97240-79-4 5284627
25
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
26
Flupenthixol Approved, Investigational, Withdrawn Phase 4 2709-56-0 17012 25137855
27
Donepezil Approved Phase 4 120014-06-4 3152
28
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
29
Sodium citrate Approved, Investigational Phase 4 68-04-2
30
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
32
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
33
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
34
Moclobemide Approved, Investigational Phase 4 71320-77-9 4235
35
Clozapine Approved Phase 4 5786-21-0 2818
36
Trimipramine Approved Phase 4 739-71-9 5584 4055
37
Protriptyline Approved Phase 4 438-60-8 4976
38
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
39
Isocarboxazid Approved Phase 4 59-63-2 3759
40
Maprotiline Approved, Investigational Phase 4 10262-69-8 4011
41
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
42
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
43
Calcium carbonate Approved, Investigational Phase 4 471-34-1
44
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
45
Ribavirin Approved Phase 4 36791-04-5 37542
46
Ondansetron Approved Phase 4 99614-02-5 4595
47
Iloperidone Approved Phase 4 133454-47-4 71360
48
Zolpidem Approved Phase 4 82626-48-0 5732
49
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
50
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9

Interventional clinical trials:

(show top 50) (show all 7314)
# Name Status NCT ID Phase Drugs
1 Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Unknown status NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
2 Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial Unknown status NCT03779789 Phase 4 Vortioxetine;Sertraline;citalopram;Escitalopram;Paroxetine;Fluoxetine;Fluvoxamine
3 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
4 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
5 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
6 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
7 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
8 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
9 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
10 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
11 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
12 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
13 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
14 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
15 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
16 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
17 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
18 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
19 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
20 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
21 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
22 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
23 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
24 Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy Unknown status NCT03187093 Phase 4 Vortioxetine;Escitalopram
25 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
26 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
27 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
28 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
29 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
30 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
31 Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
32 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
33 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
34 Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial Unknown status NCT03666494 Phase 4 Ketamine Hydrochloride;Propofol;Fentanyl
35 Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression Unknown status NCT03328052 Phase 4
36 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
37 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
38 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
39 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
40 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
41 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
42 Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy Unknown status NCT02579642 Phase 4 Ketamine;Placebo
43 Treatment Prediction in Adolescent and Adult Depression Unknown status NCT00106197 Phase 4 Bupropion
44 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
45 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
46 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
47 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
48 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
49 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148509 Phase 4 risperidone;aripiprazole;bupropion
50 Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Genetic tests related to Mental Depression:

# Genetic test Affiliating Genes
1 Mental Depression 29

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

40
Brain, Cortex, Prefrontal Cortex, Heart, Amygdala, Bone, Pituitary

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 29876)
# Title Authors PMID Year
1
Core prescription pattern of Chinese herbal medicine for depressive disorders in Taiwan: a nationwide population-based study. 61
33665095 2021
2
Gambling in patients with major depressive disorder is associated with an elevated risk of Suicide: Insights from 12-years of Nationwide inpatient sample data. 61
33676161 2021
3
Evaluation of mechanism of change in transdiagnostic cognitive behaviour therapy using single case experimental design. 61
33388441 2021
4
Attention bias modification in depression: A randomized trial using a novel, reward-based, eye-tracking approach. 61
33202263 2021
5
Treatment retention and abstinence of patients with substance use disorders according to addiction severity and psychiatry comorbidity: A six-month follow-up study in an outpatient unit. 61
33529849 2021
6
Physiological sensation word usage in social anxiety disorder with and without comorbid depression. 61
33508674 2021
7
Current application and future directions of photobiomodulation in central nervous diseases. 61
33269767 2021
8
Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. 61
33411248 2021
9
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. 61
33663326 2021
10
Differentiation of ADHD and Depression Based on Cognitive Performance. 61
31409195 2021
11
Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes. 61
33411239 2021
12
Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid. 61
33607168 2021
13
Lateral hypothalamus orexinergic inputs to lateral habenula modulate maladaptation after social defeat stress. 61
33569507 2021
14
Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. 61
33724254 2021
15
A randomized, controlled proof-of-concept trial evaluating durable effects of memory flexibility training (MemFlex) on autobiographical memory distortions and on relapse of recurrent major depressive disorder over 12 months. 61
33691266 2021
16
The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. 61
33779577 2021
17
Paradoxical effect of statin medication on depressive disorder in first-ever ischemic stroke patients: possible antidepressant-like effect prestroke and the opposite in continuous medication poststroke. 61
33724252 2021
18
Lithium toxicity and the kidney with special focus on nephrotic syndrome associated with the acute kidney injury: A case-based systematic analysis. 61
33798272 2021
19
Using the 11-item Version of the RCADS to Identify Anxiety and Depressive Disorders in Adolescents. 61
33792821 2021
20
Glatiramer acetate attenuates depressive/anxiety-like behaviors and cognitive deficits induced by post-weaning social isolation in male mice. 61
33797571 2021
21
[Interleukin 6 and depression in patients affected by Covid-19]. 61
33549331 2021
22
Interleukin 6 and depression in patients affected by Covid-19. 61
33688583 2021
23
Left Ventricular Dysfunction and Depression in Hospitalized Patients with Heart Failure. 61
33793455 2021
24
Cognitive Behavioral Analysis System of Psychotherapy for inpatients with persistent depressive disorder: a naturalistic trial on a general acute psychiatric unit. 61
31300878 2021
25
A reduced P300 prospectively predicts increased depressive severity in adults with clinical depression. 61
33433019 2021
26
Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. 61
33338557 2021
27
Which SSRI is safest for patients with CVD and major depressive disorder? 61
33735134 2021
28
Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. 61
33640861 2021
29
Characteristics of patients who received deep brain stimulation in obsessive-compulsive disorder versus major depressive disorder. 61
33639331 2021
30
Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression. 61
33127073 2021
31
Investigating regions of shared genetic variation in attention deficit/hyperactivity disorder and major depressive disorder: a GWAS meta-analysis. 61
33795730 2021
32
Increased risk of depression before and after unilateral or bilateral oophorectomy: A self-controlled case series study using a nationwide cohort in South Korea. 61
33631480 2021
33
The Efficacy of Cognitive Remediation in Depression: A Systematic Literature Review and Meta-Analysis. 61
33631438 2021
34
First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study. 61
33482315 2021
35
Effects of negativity bias on amygdala and anterior cingulate cortex activity in short and long emotional stimulation paradigms. 61
33788817 2021
36
Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy. 61
33393059 2021
37
Comparison of the level of allostatic load between patients with major depression and the general population. 61
33609985 2021
38
Differential and unique patterns of synaptic miRNA expression in dorsolateral prefrontal cortex of depressed subjects. 61
32919404 2021
39
Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark. 61
33743882 2021
40
Risk factors for natural cause mortality in a cohort of 1494 persons with serious mental illness. 61
33578064 2021
41
Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders. 61
31712721 2021
42
Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response. 61
33795631 2021
43
Stress Resilience is Associated with Hippocampal Synaptoprotection in the Female Rat Learned Helplessness Paradigm. 61
33524494 2021
44
The early postpartum period - Differences between women with and without a history of depression. 61
33588224 2021
45
Facility-Level Excess Mortality of VHA Patients With Mental Health or Substance Use Disorder Diagnoses. 61
33502219 2021
46
Photoplethysmographic Waveform Analysis for Autonomic Reactivity Assessment in Depression. 61
32960759 2021
47
Phenotypically independent profiles relevant to mental health are genetically correlated. 61
33795632 2021
48
Predictors of Depressive Symptoms and Post Traumatic Stress Disorder Among Women Engaged in Commercial Sex Work in Southern Uganda. 61
33636517 2021
49
Acceptability, safety and perceived impact of providing a fact sheet to young people about cognitive symptoms in depression. 61
32043813 2021
50
Childhood maltreatment and cognitive functioning: the role of depression, parental education, and polygenic predisposition. 61
32801319 2021

Variations for Mental Depression

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Pathways for Mental Depression

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 SERPINA3 POMC OXT MIRLET7D MIR185 MIR144

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 IL6 HTR2A HTR1A DPP4 CRH
2 female pregnancy GO:0007565 9.63 OXT CRH COMT
3 catecholamine metabolic process GO:0006584 9.49 MAOA COMT
4 neurotransmitter catabolic process GO:0042135 9.43 MAOA COMT
5 sleep GO:0030431 9.4 OXT HTR2A
6 dopamine catabolic process GO:0042420 9.37 MAOA COMT
7 serotonin receptor signaling pathway GO:0007210 9.32 HTR2A HTR1A
8 sperm ejaculation GO:0042713 9.26 SLC6A4 OXT
9 response to ether GO:0045472 9.16 OXT CRH
10 regulation of serotonin secretion GO:0014062 8.96 HTR1A CRH
11 memory GO:0007613 8.92 SLC6A4 OXT HTR2A BDNF

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Mental Depression

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....